Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.47 |
| ▸ | HPGD | P15428 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL29494817 | 0.96 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Salicylic Acid SCHEMBL6062476 | 0.96 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Salicylic Acid SCHEMBL39482 | 0.96 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Phthalic Acid SCHEMBL28406224 | 0.95 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Salicylic Acid SCHEMBL6062488 | 0.93 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Salicylic Acid SCHEMBL6062829 | 0.93 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Salicylic Acid SCHEMBL27575729 | 0.93 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4ECA12CA1 | |
| Phthalic Acid SCHEMBL840675 | 0.87 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EHMGB1NAPRT | |
| Phthalic Acid SCHEMBL15876041 | 0.85 | ALDH1A1 (0.42) | ALDH1A1HPGDKDM4EHMGB1NAPRT | |
| Salicylic Acid SCHEMBL7195263 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226007-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-07-11 | — | — | US | disclosed |
| EP-4333807-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333852-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Enalare Therapeutics Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20040253310-A1 | A opioid matrix is coated with a cellulose mixture layer; controlling the release of opioid, preventing the side effect of immediate release opioid in blood stream; water soluble and water insoluble celluloses; pain treatment | EGALET LTD. (GB) | 2004-12-16 | — | — | US | disclosed |
| US-20040234602-A1 | Polymer release system | EGALET LTD. (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2004084868-A1 | MORPHINE CONTROLLED RELEASE SYSTEM | EGALET A/S (DK) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084869-A1 | MATRIX COMPOSITIONS FOR CONTROLLED DELIVERY OF DRUG SUBSTANCES | EGALET A/S (DK) | 2004-10-07 | — | — | WO | disclosed |
| EP-1429734-A1 | CONTROLLED RELEASE SOLID DISPERSIONS | Egalet A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| EP-1429739-A1 | POLYMER RELEASE SYSTEM | Egalet A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| EP-1429744-A1 | MORPHINE POLYMER RELEASE SYSTEM | Egalet A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024430-A1 | MORPHINE POLYMER RELEASE SYSTEM | EGALET A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024426-A1 | CONTROLLED RELEASE SOLID DISPERSIONS | EGALET A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024429-A1 | POLYMER RELEASE SYSTEM | EGALET A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | ALDH1A1 2415/4885HPGD 846/4885KDM4E 4824/4885 |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ADRA2C, MTNR1B, MTNR1A | ALDH1A1 432/4885HPGD 418/4885KDM4E 3593/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | ALDH1A1 1789/4885HPGD 686/4885KDM4E 1119/4885 |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | SDHA, NDUFB7, OTC | ALDH1A1 427/4885HPGD 252/4885KDM4E 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.